Sonoma Pharmaceuticals Announces Closing of $1.6 Million Public Offering of Common Stock

About this update from Sonoma Pharmaceuticals, Inc.

[{"type":"text","content":"PETALUMA, Calif., Nov. 29, 2019 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA) today announced the closing of a public offering of 446,577 shares of common stock at a public offering price of $3.50 per share.\n The net proceeds to Sonoma Pharmaceuticals, Inc. from this offering are approximately $1.4 million after deducting the placement agent commissions and other estimated offering expenses payable by Sonoma. Sonoma Pharmaceuticals, Inc. intends to use the net proceeds from the offering for general working capital, especially to fund marketing and product development efforts. Dawson James Securities, Inc. acted as the lead placement agent and sole book runner. This offering was made pursuant to an effective shelf registration statement on Form S-3 (File No. 333-221477) previously filed with the Securities and Exchange Commission (“SEC”) and subsequently declared effective on November 27, 2017. The offering of these securities was made only by means of a prospectus and a related prospectus supplement, which have been filed with the SEC. Copies of the prospectus and prospectus supplement related to this offering may be obtained from Dawson James Securities, Inc., Attention: Prospectus Department, 1 North Federal Highway, 5th Floor, Boca Raton, FL 33432, [email protected] or toll free at 866.928.0928. Trombly Business Law, PC served as counsel to the Company. Schiff Hardin LLP served as counsel to the Placement Agent. This press release does not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Sonoma PharmaceuticalsSonoma Pharmaceuticals is a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care. The company’s products, which are sold throughout the United States and internationally, have improved outcomes for more than five million patients globally by reducing infections, itch, pain, scarring and harmful inflammatory responses. The company's headquarters are in Petaluma, California, with manufacturing operations in the United States and Latin America. European ma...

More updates from Sonoma Pharmaceuticals, Inc.